Precision Administration of Anti-thymocyte Globulin With or Without Verapamil
Phase 2
60
about 4.8 years
6–35
2 sites in CO, FL
What this study is about
This trial is testing a new way to treat type 1 diabetes. It involves using anti-thymocyte globulin (ATG) with or without verapamil, and it aims to improve how well the treatment works for each person. The goal is to find better ways to manage type 1 diabetes by understanding what makes people respond differently to the treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Anti-thymocyte globulin (ATG)
- 2.Take Placebo
- 3.Take verapamil extended release capsule
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
verapamil (Calcium channel blocker; slows heart rate and dilates vessels)
oral
Primary: AUC C-peptide between ATG and placebo values, Change in 2-hr MMTT AUC C-peptide
Endocrinology